Alkermes plc (ALKS)

Name: Alkermes plc (ALKS) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Alkermes plc (ALKS)

Stock Card

$47.75

$-1.15 (-2.35%)

As on 28-Aug-2026 13:36EDT

Market cap

$8,108 Mln

Revenue (TTM)

$1,668 Mln

P/E Ratio

127.2

P/B Ratio

4.5

Div. Yield

0 %

Value Research Rating

Quality Score

Growth Score

Valuation Score

Momentum Score

Know more

Explore 5 star rated stocks

Alkermes (ALKS) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 47.25 High: 48.82

52 Week Range

Low: 25.17 High: 55.67

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

0 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

41.4
Debt to Equity

0
Book Value

$--
EPS

$0.4
Face value

--
Shares outstanding

167,763,272

10 Years Aggregate

CFO

$704.48 Mln

EBITDA

$-213.72 Mln

Net Profit

$-921.08 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Alkermes (ALKS)	70.7	-9.4	25.4	63.2	23.7	10.5	1.4
BSE Sensex	-8.8	0.6	1.8	-4.4	6.0	6.6	10.8
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 28-Aug-2026 | #As on 26-Oct-2023

Company	2025	2023	2022	2021	2020	2019
Alkermes (ALKS)	-2.7	14.2	12.3	16.6	-2.2	-30.9
S&P Small-Cap 600	4.0	13.9	-17.4	25.3	9.6	20.9
BSE Sensex	9.1	18.7	4.4	22.0	15.8	14.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
Alkermes (ALKS)	47.8	8,108.0	1,667.7	66.1	9.4	3.6	127.2	4.5
GH Research PLC (GHRS)	27.9	2,045.5	0.0	-62.3	--	-19.5	--	5.5
Prothena (PRTA)	9.3	485.1	54.5	-44.0	-80.0	-15.5	--	1.7

Shareholding Pattern

View Details

About Alkermes (ALKS)

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The... company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland. Read more

Chairman & CEO

Mr. Richard F. Pops
Chairman & CEO

Mr. Richard F. Pops
Headquarters

Dublin
Website

https://www.alkermes.com

FAQs for Alkermes (ALKS)

What is the current share price of Alkermes plc (ALKS) Today?

The share price of Alkermes plc (ALKS) is $47.75 (NASDAQ) as of 28-Aug-2026 13:36 EDT. Alkermes plc (ALKS) has given a return of 23.65% in the last 3 years.